Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats

Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats....
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Nobuaki Egashira [verfasserIn] Yu Goto [verfasserIn] Ryota Takahashi [verfasserIn] Hikari Iba [verfasserIn] Shota Yamamoto [verfasserIn] Takuya Watanabe [verfasserIn] Kaori Kubota [verfasserIn] Takehiro Kawashiri [verfasserIn] Chise Taniguchi [verfasserIn] Shutaro Katsurabayashi [verfasserIn] Katsunori Iwasaki [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	Ibudilast Oxaliplatin Peripheral neuropathy

Übergeordnetes Werk:	In: Journal of Pharmacological Sciences - Elsevier, 2017, 147(2021), 1, Seite 114-117
Übergeordnetes Werk:	volume:147 ; year:2021 ; number:1 ; pages:114-117

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1016/j.jphs.2021.06.004

Katalog-ID:	DOAJ006181082

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ006181082
003	DE-627
005	20230309195918.0
007	cr uuu---uuuuu
008	230225s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1016/j.jphs.2021.06.004 \|2 doi
035			\|a (DE-627)DOAJ006181082
035			\|a (DE-599)DOAJ0a7262820c5a46f095577221d18b3940
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RM1-950
100	0		\|a Nobuaki Egashira \|e verfasserin \|4 aut
245	1	0	\|a Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings.
650		4	\|a Ibudilast
650		4	\|a Oxaliplatin
650		4	\|a Peripheral neuropathy
653		0	\|a Therapeutics. Pharmacology
700	0		\|a Yu Goto \|e verfasserin \|4 aut
700	0		\|a Ryota Takahashi \|e verfasserin \|4 aut
700	0		\|a Hikari Iba \|e verfasserin \|4 aut
700	0		\|a Shota Yamamoto \|e verfasserin \|4 aut
700	0		\|a Takuya Watanabe \|e verfasserin \|4 aut
700	0		\|a Kaori Kubota \|e verfasserin \|4 aut
700	0		\|a Takehiro Kawashiri \|e verfasserin \|4 aut
700	0		\|a Chise Taniguchi \|e verfasserin \|4 aut
700	0		\|a Shutaro Katsurabayashi \|e verfasserin \|4 aut
700	0		\|a Katsunori Iwasaki \|e verfasserin \|4 aut
773	0	8	\|i In \|t Journal of Pharmacological Sciences \|d Elsevier, 2017 \|g 147(2021), 1, Seite 114-117 \|w (DE-627)1760631620 \|x 13478613 \|7 nnns
773	1	8	\|g volume:147 \|g year:2021 \|g number:1 \|g pages:114-117
856	4	0	\|u https://doi.org/10.1016/j.jphs.2021.06.004 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/0a7262820c5a46f095577221d18b3940 \|z kostenfrei
856	4	0	\|u http://www.sciencedirect.com/science/article/pii/S1347861321000608 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1347-8613 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
951			\|a AR
952			\|d 147 \|j 2021 \|e 1 \|h 114-117

Indexfelder

author_variant	n e ne y g yg r t rt h i hi s y sy t w tw k k kk t k tk c t ct s k sk k i ki
matchkey_str	article:13478613:2021----::bdlssprseoailtnnuemcaiaaldnann
hierarchy_sort_str	2021
callnumber-subject-code	RM
publishDate	2021
allfields	10.1016/j.jphs.2021.06.004 doi (DE-627)DOAJ006181082 (DE-599)DOAJ0a7262820c5a46f095577221d18b3940 DE-627 ger DE-627 rakwb eng RM1-950 Nobuaki Egashira verfasserin aut Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings. Ibudilast Oxaliplatin Peripheral neuropathy Therapeutics. Pharmacology Yu Goto verfasserin aut Ryota Takahashi verfasserin aut Hikari Iba verfasserin aut Shota Yamamoto verfasserin aut Takuya Watanabe verfasserin aut Kaori Kubota verfasserin aut Takehiro Kawashiri verfasserin aut Chise Taniguchi verfasserin aut Shutaro Katsurabayashi verfasserin aut Katsunori Iwasaki verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 147(2021), 1, Seite 114-117 (DE-627)1760631620 13478613 nnns volume:147 year:2021 number:1 pages:114-117 https://doi.org/10.1016/j.jphs.2021.06.004 kostenfrei https://doaj.org/article/0a7262820c5a46f095577221d18b3940 kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861321000608 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 147 2021 1 114-117
spelling	10.1016/j.jphs.2021.06.004 doi (DE-627)DOAJ006181082 (DE-599)DOAJ0a7262820c5a46f095577221d18b3940 DE-627 ger DE-627 rakwb eng RM1-950 Nobuaki Egashira verfasserin aut Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings. Ibudilast Oxaliplatin Peripheral neuropathy Therapeutics. Pharmacology Yu Goto verfasserin aut Ryota Takahashi verfasserin aut Hikari Iba verfasserin aut Shota Yamamoto verfasserin aut Takuya Watanabe verfasserin aut Kaori Kubota verfasserin aut Takehiro Kawashiri verfasserin aut Chise Taniguchi verfasserin aut Shutaro Katsurabayashi verfasserin aut Katsunori Iwasaki verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 147(2021), 1, Seite 114-117 (DE-627)1760631620 13478613 nnns volume:147 year:2021 number:1 pages:114-117 https://doi.org/10.1016/j.jphs.2021.06.004 kostenfrei https://doaj.org/article/0a7262820c5a46f095577221d18b3940 kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861321000608 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 147 2021 1 114-117
allfields_unstemmed	10.1016/j.jphs.2021.06.004 doi (DE-627)DOAJ006181082 (DE-599)DOAJ0a7262820c5a46f095577221d18b3940 DE-627 ger DE-627 rakwb eng RM1-950 Nobuaki Egashira verfasserin aut Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings. Ibudilast Oxaliplatin Peripheral neuropathy Therapeutics. Pharmacology Yu Goto verfasserin aut Ryota Takahashi verfasserin aut Hikari Iba verfasserin aut Shota Yamamoto verfasserin aut Takuya Watanabe verfasserin aut Kaori Kubota verfasserin aut Takehiro Kawashiri verfasserin aut Chise Taniguchi verfasserin aut Shutaro Katsurabayashi verfasserin aut Katsunori Iwasaki verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 147(2021), 1, Seite 114-117 (DE-627)1760631620 13478613 nnns volume:147 year:2021 number:1 pages:114-117 https://doi.org/10.1016/j.jphs.2021.06.004 kostenfrei https://doaj.org/article/0a7262820c5a46f095577221d18b3940 kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861321000608 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 147 2021 1 114-117
allfieldsGer	10.1016/j.jphs.2021.06.004 doi (DE-627)DOAJ006181082 (DE-599)DOAJ0a7262820c5a46f095577221d18b3940 DE-627 ger DE-627 rakwb eng RM1-950 Nobuaki Egashira verfasserin aut Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings. Ibudilast Oxaliplatin Peripheral neuropathy Therapeutics. Pharmacology Yu Goto verfasserin aut Ryota Takahashi verfasserin aut Hikari Iba verfasserin aut Shota Yamamoto verfasserin aut Takuya Watanabe verfasserin aut Kaori Kubota verfasserin aut Takehiro Kawashiri verfasserin aut Chise Taniguchi verfasserin aut Shutaro Katsurabayashi verfasserin aut Katsunori Iwasaki verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 147(2021), 1, Seite 114-117 (DE-627)1760631620 13478613 nnns volume:147 year:2021 number:1 pages:114-117 https://doi.org/10.1016/j.jphs.2021.06.004 kostenfrei https://doaj.org/article/0a7262820c5a46f095577221d18b3940 kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861321000608 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 147 2021 1 114-117
allfieldsSound	10.1016/j.jphs.2021.06.004 doi (DE-627)DOAJ006181082 (DE-599)DOAJ0a7262820c5a46f095577221d18b3940 DE-627 ger DE-627 rakwb eng RM1-950 Nobuaki Egashira verfasserin aut Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings. Ibudilast Oxaliplatin Peripheral neuropathy Therapeutics. Pharmacology Yu Goto verfasserin aut Ryota Takahashi verfasserin aut Hikari Iba verfasserin aut Shota Yamamoto verfasserin aut Takuya Watanabe verfasserin aut Kaori Kubota verfasserin aut Takehiro Kawashiri verfasserin aut Chise Taniguchi verfasserin aut Shutaro Katsurabayashi verfasserin aut Katsunori Iwasaki verfasserin aut In Journal of Pharmacological Sciences Elsevier, 2017 147(2021), 1, Seite 114-117 (DE-627)1760631620 13478613 nnns volume:147 year:2021 number:1 pages:114-117 https://doi.org/10.1016/j.jphs.2021.06.004 kostenfrei https://doaj.org/article/0a7262820c5a46f095577221d18b3940 kostenfrei http://www.sciencedirect.com/science/article/pii/S1347861321000608 kostenfrei https://doaj.org/toc/1347-8613 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 147 2021 1 114-117
language	English
source	In Journal of Pharmacological Sciences 147(2021), 1, Seite 114-117 volume:147 year:2021 number:1 pages:114-117
sourceStr	In Journal of Pharmacological Sciences 147(2021), 1, Seite 114-117 volume:147 year:2021 number:1 pages:114-117
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Ibudilast Oxaliplatin Peripheral neuropathy Therapeutics. Pharmacology
isfreeaccess_bool	true
container_title	Journal of Pharmacological Sciences
authorswithroles_txt_mv	Nobuaki Egashira @@aut@@ Yu Goto @@aut@@ Ryota Takahashi @@aut@@ Hikari Iba @@aut@@ Shota Yamamoto @@aut@@ Takuya Watanabe @@aut@@ Kaori Kubota @@aut@@ Takehiro Kawashiri @@aut@@ Chise Taniguchi @@aut@@ Shutaro Katsurabayashi @@aut@@ Katsunori Iwasaki @@aut@@
publishDateDaySort_date	2021-01-01T00:00:00Z
hierarchy_top_id	1760631620
id	DOAJ006181082
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ006181082</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309195918.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jphs.2021.06.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ006181082</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ0a7262820c5a46f095577221d18b3940</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Nobuaki Egashira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ibudilast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oxaliplatin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peripheral neuropathy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yu Goto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ryota Takahashi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hikari Iba</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shota Yamamoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takuya Watanabe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kaori Kubota</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takehiro Kawashiri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chise Taniguchi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shutaro Katsurabayashi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katsunori Iwasaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Pharmacological Sciences</subfield><subfield code="d">Elsevier, 2017</subfield><subfield code="g">147(2021), 1, Seite 114-117</subfield><subfield code="w">(DE-627)1760631620</subfield><subfield code="x">13478613</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:147</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:114-117</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jphs.2021.06.004</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/0a7262820c5a46f095577221d18b3940</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1347861321000608</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1347-8613</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">147</subfield><subfield code="j">2021</subfield><subfield code="e">1</subfield><subfield code="h">114-117</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Nobuaki Egashira
spellingShingle	Nobuaki Egashira misc RM1-950 misc Ibudilast misc Oxaliplatin misc Peripheral neuropathy misc Therapeutics. Pharmacology Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats
authorStr	Nobuaki Egashira
ppnlink_with_tag_str_mv	@@773@@(DE-627)1760631620
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RM1-950
illustrated	Not Illustrated
issn	13478613
topic_title	RM1-950 Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats Ibudilast Oxaliplatin Peripheral neuropathy
topic	misc RM1-950 misc Ibudilast misc Oxaliplatin misc Peripheral neuropathy misc Therapeutics. Pharmacology
topic_unstemmed	misc RM1-950 misc Ibudilast misc Oxaliplatin misc Peripheral neuropathy misc Therapeutics. Pharmacology
topic_browse	misc RM1-950 misc Ibudilast misc Oxaliplatin misc Peripheral neuropathy misc Therapeutics. Pharmacology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Journal of Pharmacological Sciences
hierarchy_parent_id	1760631620
hierarchy_top_title	Journal of Pharmacological Sciences
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1760631620
title	Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats
ctrlnum	(DE-627)DOAJ006181082 (DE-599)DOAJ0a7262820c5a46f095577221d18b3940
title_full	Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats
author_sort	Nobuaki Egashira
journal	Journal of Pharmacological Sciences
journalStr	Journal of Pharmacological Sciences
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2021
contenttype_str_mv	txt
container_start_page	114
author_browse	Nobuaki Egashira Yu Goto Ryota Takahashi Hikari Iba Shota Yamamoto Takuya Watanabe Kaori Kubota Takehiro Kawashiri Chise Taniguchi Shutaro Katsurabayashi Katsunori Iwasaki
container_volume	147
class	RM1-950
format_se	Elektronische Aufsätze
author-letter	Nobuaki Egashira
doi_str_mv	10.1016/j.jphs.2021.06.004
author2-role	verfasserin
title_sort	ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats
callnumber	RM1-950
title_auth	Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats
abstract	Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings.
abstractGer	Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings.
abstract_unstemmed	Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ
container_issue	1
title_short	Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats
url	https://doi.org/10.1016/j.jphs.2021.06.004 https://doaj.org/article/0a7262820c5a46f095577221d18b3940 http://www.sciencedirect.com/science/article/pii/S1347861321000608 https://doaj.org/toc/1347-8613
remote_bool	true
author2	Yu Goto Ryota Takahashi Hikari Iba Shota Yamamoto Takuya Watanabe Kaori Kubota Takehiro Kawashiri Chise Taniguchi Shutaro Katsurabayashi Katsunori Iwasaki
author2Str	Yu Goto Ryota Takahashi Hikari Iba Shota Yamamoto Takuya Watanabe Kaori Kubota Takehiro Kawashiri Chise Taniguchi Shutaro Katsurabayashi Katsunori Iwasaki
ppnlink	1760631620
callnumber-subject	RM - Therapeutics and Pharmacology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1016/j.jphs.2021.06.004
callnumber-a	RM1-950
up_date	2024-07-03T19:26:58.772Z
_version_	1803587230131814400
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ006181082</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309195918.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jphs.2021.06.004</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ006181082</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ0a7262820c5a46f095577221d18b3940</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Nobuaki Egashira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Oxaliplatin is a key drug used in the management of solid tumors, such as colorectal cancer; however, it causes peripheral neuropathy. In this study, we investigated the effect of ibudilast, a phosphodiesterase inhibitor, on oxaliplatin-induced mechanical allodynia and histological changes in rats. Ibudilast (7.5 mg/kg, i.p., 5 times per week) reduced mechanical allodynia and histological changes induced by oxaliplatin (4 mg/kg, i.p., twice a week). In contrast, ibudilast (0.01–10 μM) had no effect on oxaliplatin-induced tumor cytotoxicity in murine colon adenocarcinoma 26 cells. These findings suggest that ibudilast could be useful for preventing oxaliplatin-induced peripheral neuropathy in clinical settings.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ibudilast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oxaliplatin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Peripheral neuropathy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yu Goto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ryota Takahashi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hikari Iba</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shota Yamamoto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takuya Watanabe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kaori Kubota</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Takehiro Kawashiri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chise Taniguchi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Shutaro Katsurabayashi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Katsunori Iwasaki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Journal of Pharmacological Sciences</subfield><subfield code="d">Elsevier, 2017</subfield><subfield code="g">147(2021), 1, Seite 114-117</subfield><subfield code="w">(DE-627)1760631620</subfield><subfield code="x">13478613</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:147</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:114-117</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jphs.2021.06.004</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/0a7262820c5a46f095577221d18b3940</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/article/pii/S1347861321000608</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1347-8613</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">147</subfield><subfield code="j">2021</subfield><subfield code="e">1</subfield><subfield code="h">114-117</subfield></datafield></record></collection>
score	7.4005775

Nicht das Richtige dabei?

Schreiben Sie uns!

Ibudilast suppresses oxaliplatin-induced mechanical allodynia and neurodegeneration in rats

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?